|
|
|
Volumn 20, Issue 1, 2015, Pages 350-351
|
|
Targeted immunotherapies overtaking emerging oncology market value based growth
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
MONOCLONAL ANTIBODY;
PROTEIN KINASE INHIBITOR;
ANTINEOPLASTIC AGENT;
CANCER IMMUNOTHERAPY;
CANCER MORTALITY;
CANCER SURVIVAL;
CLINICAL PRACTICE;
COST EFFECTIVENESS ANALYSIS;
EUROPEAN;
HUMAN;
IMMUNOTHERAPY;
LETTER;
MORBIDITY;
ONCOLOGY;
QUALITY OF LIFE;
REIMBURSEMENT;
SURVIVAL RATE;
USSR;
BUDGET;
COMMERCIAL PHENOMENA;
COST BENEFIT ANALYSIS;
COST CONTROL;
DRUG COST;
DRUG INDUSTRY;
ECONOMICS;
HEALTH CARE COST;
HEALTH CARE DELIVERY;
MOLECULARLY TARGETED THERAPY;
MORTALITY;
NEOPLASMS;
SERBIA;
SUPPLY AND DISTRIBUTION;
TIME;
TRENDS;
ANTINEOPLASTIC AGENTS;
BUDGETS;
COMMERCE;
COST CONTROL;
COST-BENEFIT ANALYSIS;
DRUG COSTS;
DRUG INDUSTRY;
HEALTH EXPENDITURES;
HEALTH SERVICES ACCESSIBILITY;
HUMANS;
IMMUNOTHERAPY;
MEDICAL ONCOLOGY;
MOLECULAR TARGETED THERAPY;
NEOPLASMS;
SERBIA;
TIME FACTORS;
|
|
EID: 84928701501
PISSN: 11070625
EISSN: None
Source Type: Journal
DOI: None Document Type: Letter |
|
Times cited : (5)
|
|
References (5)
|
